There have been frequent discussions about the possible use of CBD in healthcare based on the effectiveness of hemp-derived products. Yet, no concrete steps were taken until now. Today, the CMS program has been activated, allowing hemp-derived cannabinoid products to reach eligible Medicare candidates. It reflects a major decision taken by the federal government regarding products derived from the cannabis plant. If you are new to this field, it will be helpful to know that CBD is a natural chemical compound obtained from a type of cannabis plant. The cannabis plant can be classified into marijuana and hemp. Hemp-derived CBD is considered safer as it does not cause psychoactive effects. It is also believed to support patients who have insomnia, anxiety, and chronic pain. However, only select hemp products are permitted for use under this program.
Under the new CBD Medicare incentive program, products that contain less than or approximately 0.3% delta-9 THC can be considered for senior patients. However, the cost of these products can be covered only up to USD 500 per year. This pilot program is currently operating at a restricted level, with access limited to Medicare patients and physicians affiliated with healthcare organizations supporting one of the three care models, such as cancer, long-term care, or senior care. What makes this program sound safer?
- The choice of care models
Only three care models supported by the CMS Innovation Center have been included under the incentive scheme as of now. They have been mentioned above. Each healthcare organization participating in any of these models is required to provide an implementation plan for CMS approval. Since the areas are well-defined, it will be easier to collect data on the role of hemp products in healthcare regimens before expanding the reach. All participants must furnish the authorities with quarterly reports covering necessary points, including choice of hemp products, dosage details, beneficiary eligibility, and monitoring processes.
- Product and clinical safeguards
As a general rule, no hemp product authorized for use under physician guidance should contain more than 0.3 percent delta-9 THC and 3 mg of total THC per serving. Inhalable products are barred; only oral options are considered under this program. However, these must also be tested for quality by a third-party lab. It is also necessary to ensure that these products are made from ethically sourced ingredients. As for clinical oversight, physicians can decide on the use of hemp products only after explaining their benefits and risks to eligible Medicare patients. If patients show interest, the next steps can be taken. Doctors need to account for their patients’ current medications and conduct regular follow-ups. These measures help prevent the risk of abuse while ensuring patient safety.
- Operational and financial considerations
Participating healthcare organizations are responsible for managing both operations and product costs. They can work only with approved hemp product suppliers. Their inventory management system must be well-established. All clinical members should be well-versed in protocols for hemp products. Since the program has integrity requirements in place, participants cannot use marketing tools to promote the supply of hemp products. Also, the integration of care models in the program shows that hemp products are not treated as a separate therapeutic intervention. They are considered part of overall patient outcomes.
Nevertheless, not everyone can benefit from this new program. It does not mean these individuals cannot access safe and high-quality hemp-derived products. If you are one of them, you can search for an online store that sells high-quality CBD products at farm-direct pricing.